Tsubota Laboratory Incorporated

4890

JP3535700003

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
360 ^JPY	0.00%		+4.35%	+7.46%

2022	Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022.	CI
2022	Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022.	CI

Tsubota Laboratory Incorporated has filed an IPO.

May 20, 2022 at 12:00 am EDT

Tsubota Laboratory Incorporated has filed an IPO.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 3,840,000

Transaction Features: Sponsor Backed Offering

Latest news about Tsubota Laboratory Incorporated

Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022.	22-12-18	CI
Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022.	22-09-19	CI
Tsubota Laboratory Incorporated has completed an IPO in the amount of Ã‘1.8048 billion.	22-06-23	CI
Tsubota Laboratory Incorporated has filed an IPO.	22-05-20	CI

Chart Tsubota Laboratory Incorporated

Duration

Period

More charts

Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TSUBOTA LABORATORY INCORPORATED	+7.46%	58.5M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.37%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B